{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-107339","form_type":"8-K","ticker":"LYRA","cik":"0001327273","company_name":"Lyra Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.685787+00:00","generated_at":"2026-05-17T14:21:31.399420+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint","bullets":["Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.","Cash $29.8M at June 30, 2025; $5.0M gross financing extends runway into Q3 2026.","ENLIGHTEN 2 Phase 3 met primary endpoint: 3CS improvement -1.13 (p=0.0078) at week 24; key secondary endpoints also met.","Preparing for Type C meeting with FDA in H2 2025 to align on NDA submission path for LYR-210 in CRS without nasal polyps.","Completed 1-for-50 reverse stock split in May; regained Nasdaq minimum bid compliance."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-107339","json":"https://secwatch.observer/filing/0000950170-25-107339.json","markdown":"https://secwatch.observer/filing/0000950170-25-107339.md","text":"https://secwatch.observer/filing/0000950170-25-107339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1327273/000095017025107339/0000950170-25-107339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1327273/000095017025107339/lyra-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:21:31.399420+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}